SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Entry into a Material Definitive Agreement

SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.

Story continues below

SPECTRUM PHARMACEUTICALS INC Exhibit
EX-10.1 2 d691129dex101.htm EX-10.1 EX-10.1 Exhibit 10.1       ASSET PURCHASE AGREEMENT between SPECTRUM PHARMACEUTICALS,…
To view the full exhibit click here

About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

An ad to help with our costs